It only took two paragraphs for AstraZeneca to be in the spotlight again. Laconic, A declaration broadcast this Tuesday in the United States by the National Institute of Allergies and Infectious Diseases (NIAID) comes to throw a new pavement in the pond of the bio-pharmaceutical company, already very cloudy after the suspension, by several European countries, of its vaccine as a result of the onset of circulatory problems in some patients.
What does this umpteenth rebound consist of? Fresh out of the turmoil, AstraZeneca publishes on Monday A press release enthusiastic: the intermediate results of clinical trial conducted in particular in the United States and based on 32,449 participants show an efficacy rate – for two doses of vaccine dispensed four weeks apart – of 79% in preventing symptomatic forms of Covid-19 and of 100% in the prevention of severe forms of illness and hospitalizations. In people over 65, the vaccine is 80% effective, according to the company.